Overview

This trial is active, not recruiting.

Condition phenylketonuria (pku)
Treatments bmn165 20mg/day, bmn165 40mg/day, placebo
Phase phase 3
Sponsor BioMarin Pharmaceutical
Start date July 2013
End date June 2017
Trial size 250 participants
Trial identifier NCT01889862, 165-302

Summary

The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose treatment
Arm
(Active Comparator)
BMN165 20mg/day self-administered daily
bmn165 20mg/day PEG-PAL
Two different doses of BMN165 compared to each other and compared to placebo
(Placebo Comparator)
Low Placebo self-administered daily
placebo Dextran 40
Two different doses of BMN165 compared to each other and compared to placebo
(Active Comparator)
BMN165 40mg/day self-administered daily
bmn165 40mg/day PEG-PAL
Two different doses of BMN165 compared to each other and compared to placebo
(Placebo Comparator)
High Placebo self-administered daily
placebo Dextran 40
Two different doses of BMN165 compared to each other and compared to placebo

Primary Outcomes

Measure
Incidence of adverse events experienced by subjects.
time frame: Weekly throughout study.

Secondary Outcomes

Measure
Cognitive and mood symptoms BMN 165
time frame: Throughout the study
Plasma Phenylalanine (phe) levels
time frame: Throughout the study

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

INCLUSION CRITERIA Individuals eligible to participate in this study must meet all of the following criteria: - Have completed a prior BMN 165 study (PAL-003 or 165-301) prior to screening - Have had a stable BMN 165 dose regimen for at least 14 days prior to screening - Are at least 18 y/o and no older than 70 y/o at screening - Subjects who are < 18 y/o and are already enrolled into Study 165-301 under Amendment #1 (10JAN2014) may enroll into this study - Has identified a person who is ≥ 18 y/o who has the neurocognitive and linguistic capacities to comprehend and complete the POMS-Observer rated scale - Has identified a competent person(s) ≥ 18 y/o who can observe the subject during study drug administration at certain points in the study - A home healthcare nurse may perform the study drug observations - Are willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to any research-related procedures; for minors, parent or guardian provides written consent and assent may be requested - Are willing and able to comply with all study procedures - For females of childbearing potential, a negative pregnancy test at screening and willing to have additional pregnancy tests during the study - If sexually active, willing to use two acceptable methods of contraception during and for 4 weeks after the study - Males post vasectomy for 2 years with no known pregnancies do not need to use any other forms of contraception during the study. - Females who have been in menopause for at least 2 years, have had a tubal ligation at least 1 year prior to screening, or have had a total hysterectomy do not need to use any other forms of contraception during the study. - Have received documented approval from a study dietitian confirming that the subject is capable of maintaining their diet - Have neurocognitive and linguistic capacities to comprehend and answer investigator's prompts for the ADHD-RS Investigator rated instrument and to complete the POMS-Subject rated scale - If applicable, maintained stable dose of medication for ADHD, depression, anxiety, or other psychiatric disorder ≥8 weeks prior to enrollment and willing to maintain stable dose throughout study unless a change is medically indicated - General good health, as evidenced by physical examination, clinical laboratory evaluations, and ECG tests at screening Exclusion Criteria Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study: - Use of any investigational product (except BMN 165) or investigational medical device within 30 days prior to screening or requirement for any investigational agent prior to completion of all scheduled study assessments - Use of any medication (except BMN 165) intended to treat PKU, including the use of large neutral amino acids, within 2 days prior to the administration of study drug - Have known hypersensitivity to Dextran® or components of Dextran - Use or planned use of any injectable drugs containing PEG (except for BMN 165), including medroxyprogesterone injection, within 3 months prior to screening and during study participation - Current use of levodopa - A positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C antibody - A history of organ transplantation or taking chronic immunosuppressive therapy - A history of substance abuse in the past 12 months or current alcohol or drug abuse - Current participation in the Kuvan registry study (PKUDOS). Patients may discontinue the PKUDOS registry trial to allow enrollment in this study - Pregnant or breastfeeding at screening or planning to become pregnant (self or partner) or breastfeed at any time during the study - Concurrent disease or condition that would interfere with study participation or safety. - Major surgery planned during the study period - Any condition that in the view of the investigator, places the subject at high risk of poor treatment compliance or terminating early from the study - ALT concentration at least 2x the upper limit of normal - Creatinine at least 1.5x the upper limit of normal

Additional Information

Official title A Four-Part, Phase 3, Randomized, Double-Blind, Placebo- Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self-Administered by Adults With Phenylketonuria (PKU)
Description 165-302 is a Phase 3, 4 Part, Randomized, Double-Blind, Placebo-Controlled, Discontinuation Study to Evaluate the Efficacy and Safety of Self Administered Subcutaneous Injections of BMN 165 by Adults With PKU. This study is open only to adults who have been exposed to BMN165 in a previous study. Study BMN 165-302 is a four-part, Phase 3 study. - PART 1: Open-label period - PART 2: A Randomized, double-blind, placebo-controlled period of 8 weeks - PART 3: PK (plasma BMN 165) and PD (plasma Phe) assessment. - Part 4: A long-term, open-label extension study.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by BioMarin Pharmaceutical.